SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lincoln Pharmaceuticals informs about resignation of director

22 Feb 2024 Evaluate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Lincoln Pharmaceuticals has informed that the Company has received Resignation letter dated February 15, 2024 from Meha Patel (DIN: 07254852) resigning as Non-Executive Independent Woman Director of the Company due to personal reasons. The resignation will become effective from the date of receipt of the said letter by Company i.e. from February 16, 2024. Consequently, she shall also cease to be a Chairperson of the Audit Committee, Nomination and Remuneration Committee, Stakeholder Relationship Committee, Risk Management Committee and member of Corporate Social Responsibility Committee of the Board. Meha Patel (DIN: 07254852) has confirmed that there are no other material reasons for her resignation other than those mentioned in her resignation letter. Disclosures required under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 read with SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure-I. The letter of resignation received from Meha Patel is enclosed as Annexure - II.

The above information is a part of company’s filings submitted to BSE.

Lincoln Pharma Share Price

641.25 -4.15 (-0.64%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×